Potratz Jenny C, Guddorf Sarah, Ahlmann Martina, Tekaat Maria, Rossig Claudia, Omran Heymut, Masjosthusmann Katja, Groll Andreas H
Department of General Pediatrics, University Children's Hospital Münster, Münster, Germany.
Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.
Front Oncol. 2021 Apr 27;11:664928. doi: 10.3389/fonc.2021.664928. eCollection 2021.
Extracorporeal membrane oxygenation (ECMO) is a rescue therapy for severe respiratory and/or circulatory failure. Few data exist on the potential benefit of ECMO in immunocompromised pediatric patients with cancer and/or hematopoietic cell transplantation (HCT). Over a period of 12 years, eleven (1.9%) of 572 patients with new diagnosis of leukemia/lymphoma and nine (3.5%) of 257 patients post allogeneic HCT underwent ECMO at our center. Five (45%) and two (22%) patients, respectively, survived to hospital discharge with a median event-free survival of 4.2 years. Experiences and outcomes in this cohort may aid clinicians and families when considering ECMO for individual patients.
体外膜肺氧合（ECMO）是一种用于治疗严重呼吸和/或循环衰竭的挽救性疗法。关于ECMO对免疫功能低下的癌症患儿和/或造血细胞移植（HCT）患儿的潜在益处，相关数据较少。在12年的时间里，我们中心572例新诊断白血病/淋巴瘤患者中有11例（1.9%）、257例异基因造血干细胞移植术后患者中有9例（3.5%）接受了ECMO治疗。分别有5例（45%）和2例（22%）患者存活至出院，无事件生存期的中位数为4.2年。该队列中的经验和结果可能有助于临床医生和患者家属在考虑为个体患者使用ECMO时提供参考。
